S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Cellectis Stock Forecast, Price & News

-0.11 (-1.63%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
224,769 shs
Average Volume
277,505 shs
Market Capitalization
$301.06 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter.

Cellectis logo

About Cellectis

Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. It offers Gene editing and Immuno-oncology. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.


Henry James International Management Inc.
January 18, 2022 |  finance.yahoo.com
Form 6-K Cellectis SA For: Dec 11 - StreetInsider.com
December 13, 2021 |  streetinsider.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$82.46 million
Book Value
$7.27 per share


Net Income
$-81.07 million
Net Margins
Pretax Margin




Free Float
Market Cap
$301.06 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.05 out of 5 stars

Medical Sector

567th out of 1,419 stocks

Biological Products, Except Diagnostic Industry

89th out of 206 stocks

Analyst Opinion: 3.2Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -

Cellectis (NASDAQ:CLLS) Frequently Asked Questions

Is Cellectis a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Cellectis stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLLS, but not buy additional shares or sell existing shares.
View analyst ratings for Cellectis
or view top-rated stocks.

How has Cellectis' stock price been impacted by Coronavirus (COVID-19)?

Cellectis' stock was trading at $11.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CLLS shares have decreased by 42.1% and is now trading at $6.62.
View which stocks have been most impacted by COVID-19

When is Cellectis' next earnings date?

Cellectis is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Cellectis

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) released its quarterly earnings data on Wednesday, December, 8th. The biotechnology company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by $0.02. Cellectis had a negative net margin of 188.02% and a negative trailing twelve-month return on equity of 44.64%.
View Cellectis' earnings history

What price target have analysts set for CLLS?

7 brokerages have issued 12-month target prices for Cellectis' shares. Their forecasts range from $10.00 to $33.00. On average, they expect Cellectis' share price to reach $21.80 in the next year. This suggests a possible upside of 229.3% from the stock's current price.
View analysts' price targets for Cellectis
or view top-rated stocks among Wall Street analysts.

Who are Cellectis' key executives?

Cellectis' management team includes the following people:
  • André Choulika, Chief Executive Officer & Director
  • Eric Dutang, Chief Financial Officer
  • Philippe Duchateau, Chief Scientific Officer
  • Francisco J. Esteva, Vice President-Clinical Development
  • Carrie Brownstein, Chief Medical Officer

What is André Choulika's approval rating as Cellectis' CEO?

4 employees have rated Cellectis CEO André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among Cellectis' employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Who are Cellectis' major shareholders?

Cellectis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (2.37%) and Exchange Traded Concepts LLC (0.76%).

Which major investors are buying Cellectis stock?

CLLS stock was acquired by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, and Baillie Gifford & Co..

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $6.62.

How much money does Cellectis make?

Cellectis has a market capitalization of $301.06 million and generates $82.46 million in revenue each year. The biotechnology company earns $-81.07 million in net income (profit) each year or ($2.93) on an earnings per share basis.

How many employees does Cellectis have?

Cellectis employs 340 workers across the globe.

What is Cellectis' official website?

The official website for Cellectis is www.cellectis.com.

Where are Cellectis' headquarters?

Cellectis is headquartered at 8 RUE DE LA CROIX JARRY, PARIS I0, 75013.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at (318) 169-1600, via email at [email protected], or via fax at 33-1-81-69-16-06.

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.